[Explanation] From November 5th to 10th, the 5th China International Import Expo was held in Shanghai.

Many exhibitors have increased their investment in China through the CIIE, changing from exhibitors to investors, and the "spillover effect" of the CIIE is constantly emerging.

　　Danaher, which has participated in the exhibition for five consecutive years, released a number of local achievements of the "Innovation in China" strategy, with special emphasis on continuing to increase the Chinese market.

At present, Danaher has 14 local manufacturing bases and nearly 20 R&D teams in China.

Many of its sub-brands have announced plans to increase capital and expand production in many local R&D and manufacturing bases in China, covering the Yangtze River Delta, Beijing-Tianjin-Hebei, and the Greater Bay Area, involving biotechnology, medical diagnosis, environmental and application solutions and other fields.

　　[Concurrent] Peng Yang, President of Danaher Global Vice President China Group

　　Simply put, we will increase our investment in China.

Including our Situofan's China Science and Technology Innovation Center, our investment will add another 60 million.

We will also invest about 70 million in Yizhuang (the Pall factory in Beijing).

　　[Explanation] In the eyes of many exhibitors, the CIIE is often regarded as an "accelerator" for the approval and listing of domestic innovative drugs.

Zhang Lei, vice president of Bayer China Communications, said frankly that once, it took a few years for an overseas innovative drug to be approved from overseas to China.

Today, thanks to the "spillover effect" of the China International Import Expo, overseas innovative drugs are accelerating their launch.

　　[Concurrent] Zhang Lei, Vice President of Bayer China Communications

　　At Bayer's booth this year, we exhibited two innovative drugs, one for patients with chronic heart failure, and the other for our patients with diabetes and kidney disease, Keshenda.

These two innovative drugs are actually innovative drugs at the 3rd and 4th CIIE. Through a window effect like the CIIE, we have achieved the global simultaneous approval of these two innovative drugs. Approved at the same time.

　　[Explanation] Ye Tiancheng, general manager of Edwards Life Sciences Greater China, is also deeply touched by the powerful "spillover effect" of China International Import Expo.

　　[Concurrent] Ye Tiancheng, General Manager of Edward Life Sciences Greater China

　　I only got the certificate for that product in 2020, and we made our debut at the CIIE in the same year.

Through the China International Import Expo, we quickly launched that product, because we have covered more than 70 hospitals in more than 20 provinces and cities.

　　[Explanation] Over the past five years, China's absorption of foreign capital has continued to grow, and more and more stories of China's entry into the Expo are being written. The Chinese market is "the world's market, the shared market, and everyone's market", which has become an international consensus.

　　Li Qiuying, Chen Congyao and Xu Mingrui reported from Shanghai

Responsible editor: [Yu Xiao]